Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sagimet Biosciences Inc SGMT

Healthcare Biotechnology
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor... see more

Recent & Breaking News (NDAQ:SGMT)

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

GlobeNewswire May 16, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire May 15, 2024

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

GlobeNewswire May 7, 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

GlobeNewswire May 6, 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

GlobeNewswire April 22, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

GlobeNewswire March 27, 2024

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

GlobeNewswire March 25, 2024

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire March 25, 2024

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire February 29, 2024

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

GlobeNewswire January 25, 2024

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

GlobeNewswire January 23, 2024

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

GlobeNewswire January 22, 2024

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

GlobeNewswire December 4, 2023

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

GlobeNewswire November 28, 2023

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 22, 2023

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

GlobeNewswire November 13, 2023

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

GlobeNewswire November 10, 2023

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

GlobeNewswire October 24, 2023

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

GlobeNewswire October 18, 2023

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

GlobeNewswire September 27, 2023